Genetics and Osteoporosis

Omar Al Bagha, Stuart H. Ralston

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

Over the past 10 years, many advances have been made in understanding the mechanisms by which genetic factors regulate susceptibility to osteoporosis. It has become clear from studies in man and experimental animals that different genes regulate BMD at different skeletal sites and in men and women. Linkage studies have identified several chromosomal regions that regulate BMD, but only a few causative genes have been discovered so far using this approach. In contrast, significant advances have been made in identifying the genes that cause monogenic bone diseases, and polymorphic variation in some of these genes has been found to contribute to the genetic regulation of BMD in the normal population. Other genes that have been investigated as possible candidates for susceptibility to osteoporosis because of their role in bone biology, such as vitamin D, have yielded mixed results. Many candidate gene association studies have been underpowered, and meta-analysis has been used to try to confirm or refute potential associations and gain a better estimate of their true effect size in the population. Most of the genetic variants that confer susceptibility to osteoporosis remain to be discovered. It is likely that new techniques such as whole-genome association will provide new insights into the genetic determinants of osteoporosis and will help to identify genes of modest effect size. From a clinical standpoint, genetic variants that are found to predispose to osteoporosis will advance our understanding of the pathophysiology of the disease. They could be developed as diagnostic genetic tests or form molecular targets for design of new drugs for the prevention and treatment of osteoporosis and other bone diseases.

Original languageEnglish
Pages (from-to)659-680
Number of pages22
JournalRheumatic Disease Clinics of North America
Volume32
Issue number4
DOIs
Publication statusPublished - Nov 2006
Externally publishedYes

Fingerprint

Osteoporosis
Genes
Bone Diseases
Drug Design
Genetic Association Studies
Population Density
Routine Diagnostic Tests
Vitamin D
Meta-Analysis
Genome
Bone and Bones
Population

ASJC Scopus subject areas

  • Rheumatology

Cite this

Genetics and Osteoporosis. / Al Bagha, Omar; Ralston, Stuart H.

In: Rheumatic Disease Clinics of North America, Vol. 32, No. 4, 11.2006, p. 659-680.

Research output: Contribution to journalReview article

Al Bagha, Omar ; Ralston, Stuart H. / Genetics and Osteoporosis. In: Rheumatic Disease Clinics of North America. 2006 ; Vol. 32, No. 4. pp. 659-680.
@article{7935f8908a604f8cae9391c47251625b,
title = "Genetics and Osteoporosis",
abstract = "Over the past 10 years, many advances have been made in understanding the mechanisms by which genetic factors regulate susceptibility to osteoporosis. It has become clear from studies in man and experimental animals that different genes regulate BMD at different skeletal sites and in men and women. Linkage studies have identified several chromosomal regions that regulate BMD, but only a few causative genes have been discovered so far using this approach. In contrast, significant advances have been made in identifying the genes that cause monogenic bone diseases, and polymorphic variation in some of these genes has been found to contribute to the genetic regulation of BMD in the normal population. Other genes that have been investigated as possible candidates for susceptibility to osteoporosis because of their role in bone biology, such as vitamin D, have yielded mixed results. Many candidate gene association studies have been underpowered, and meta-analysis has been used to try to confirm or refute potential associations and gain a better estimate of their true effect size in the population. Most of the genetic variants that confer susceptibility to osteoporosis remain to be discovered. It is likely that new techniques such as whole-genome association will provide new insights into the genetic determinants of osteoporosis and will help to identify genes of modest effect size. From a clinical standpoint, genetic variants that are found to predispose to osteoporosis will advance our understanding of the pathophysiology of the disease. They could be developed as diagnostic genetic tests or form molecular targets for design of new drugs for the prevention and treatment of osteoporosis and other bone diseases.",
author = "{Al Bagha}, Omar and Ralston, {Stuart H.}",
year = "2006",
month = "11",
doi = "10.1016/j.rdc.2006.08.001",
language = "English",
volume = "32",
pages = "659--680",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Genetics and Osteoporosis

AU - Al Bagha, Omar

AU - Ralston, Stuart H.

PY - 2006/11

Y1 - 2006/11

N2 - Over the past 10 years, many advances have been made in understanding the mechanisms by which genetic factors regulate susceptibility to osteoporosis. It has become clear from studies in man and experimental animals that different genes regulate BMD at different skeletal sites and in men and women. Linkage studies have identified several chromosomal regions that regulate BMD, but only a few causative genes have been discovered so far using this approach. In contrast, significant advances have been made in identifying the genes that cause monogenic bone diseases, and polymorphic variation in some of these genes has been found to contribute to the genetic regulation of BMD in the normal population. Other genes that have been investigated as possible candidates for susceptibility to osteoporosis because of their role in bone biology, such as vitamin D, have yielded mixed results. Many candidate gene association studies have been underpowered, and meta-analysis has been used to try to confirm or refute potential associations and gain a better estimate of their true effect size in the population. Most of the genetic variants that confer susceptibility to osteoporosis remain to be discovered. It is likely that new techniques such as whole-genome association will provide new insights into the genetic determinants of osteoporosis and will help to identify genes of modest effect size. From a clinical standpoint, genetic variants that are found to predispose to osteoporosis will advance our understanding of the pathophysiology of the disease. They could be developed as diagnostic genetic tests or form molecular targets for design of new drugs for the prevention and treatment of osteoporosis and other bone diseases.

AB - Over the past 10 years, many advances have been made in understanding the mechanisms by which genetic factors regulate susceptibility to osteoporosis. It has become clear from studies in man and experimental animals that different genes regulate BMD at different skeletal sites and in men and women. Linkage studies have identified several chromosomal regions that regulate BMD, but only a few causative genes have been discovered so far using this approach. In contrast, significant advances have been made in identifying the genes that cause monogenic bone diseases, and polymorphic variation in some of these genes has been found to contribute to the genetic regulation of BMD in the normal population. Other genes that have been investigated as possible candidates for susceptibility to osteoporosis because of their role in bone biology, such as vitamin D, have yielded mixed results. Many candidate gene association studies have been underpowered, and meta-analysis has been used to try to confirm or refute potential associations and gain a better estimate of their true effect size in the population. Most of the genetic variants that confer susceptibility to osteoporosis remain to be discovered. It is likely that new techniques such as whole-genome association will provide new insights into the genetic determinants of osteoporosis and will help to identify genes of modest effect size. From a clinical standpoint, genetic variants that are found to predispose to osteoporosis will advance our understanding of the pathophysiology of the disease. They could be developed as diagnostic genetic tests or form molecular targets for design of new drugs for the prevention and treatment of osteoporosis and other bone diseases.

UR - http://www.scopus.com/inward/record.url?scp=34247135040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247135040&partnerID=8YFLogxK

U2 - 10.1016/j.rdc.2006.08.001

DO - 10.1016/j.rdc.2006.08.001

M3 - Review article

VL - 32

SP - 659

EP - 680

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

IS - 4

ER -